Compare Stocks: TNYA, VSTM, AVTE, and EIKN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$20.84 -2.1%	$21.35	$89.95 ▼ $99.05	$604.05M	0.95	53,591 shs	357,936 shs
EIKN Eikon Therapeutics	$10.57 -3.7%	$10.55	$7.90 ▼ $17.40	$572.52M	N/A	381,474 shs	132,380 shs
TNYA Tenaya Therapeutics	$0.68 -1.3%	$0.76	$0.53 ▼ $2.35	$152.72M	2.83	3.56 million shs	929,534 shs
VSTM Verastem	$7.12 -1.4%	$5.80	$3.43 ▼ $11.24	$644.81M	0.26	2.20 million shs	580,867 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	0.00%	-2.34%	+4.20%	-0.95%	+163.80%
EIKN Eikon Therapeutics	0.00%	-3.60%	+19.22%	+1.76%	+1,097,999,900.00%
TNYA Tenaya Therapeutics	0.00%	-1.03%	-6.78%	-20.68%	-38.93%
VSTM Verastem	0.00%	+4.79%	+24.48%	+72.32%	-21.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$20.84 -2.1%	$21.35	$89.95 ▼ $99.05	$604.05M	0.95	53,591 shs	357,936 shs
EIKN Eikon Therapeutics	$10.57 -3.7%	$10.55	$7.90 ▼ $17.40	$572.52M	N/A	381,474 shs	132,380 shs
TNYA Tenaya Therapeutics	$0.68 -1.3%	$0.76	$0.53 ▼ $2.35	$152.72M	2.83	3.56 million shs	929,534 shs
VSTM Verastem	$7.12 -1.4%	$5.80	$3.43 ▼ $11.24	$644.81M	0.26	2.20 million shs	580,867 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	0.00%	-2.34%	+4.20%	-0.95%	+163.80%
EIKN Eikon Therapeutics	0.00%	-3.60%	+19.22%	+1.76%	+1,097,999,900.00%
TNYA Tenaya Therapeutics	0.00%	-1.03%	-6.78%	-20.68%	-38.93%
VSTM Verastem	0.00%	+4.79%	+24.48%	+72.32%	-21.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
EIKN Eikon Therapeutics	2.38	Hold	$25.00	136.52% Upside
TNYA Tenaya Therapeutics	2.86	Moderate Buy	$4.00	487.29% Upside
VSTM Verastem	2.80	Moderate Buy	$13.83	94.29% Upside

Current Analyst Ratings Breakdown

Latest TNYA, VSTM, AVTE, and EIKN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	EIKN Eikon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/14/2026	EIKN Eikon Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underperform	$5.00 ➝ $4.00
8/10/2026	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$14.00 ➝ $13.00
8/7/2026	VSTM Verastem	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$14.00 ➝ $12.00
8/3/2026	EIKN Eikon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
7/28/2026	TNYA Tenaya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/7/2026	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$15.00 ➝ $14.00
7/2/2026	TNYA Tenaya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/2/2026	VSTM Verastem	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
6/24/2026	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
6/24/2026	VSTM Verastem	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	$1.34M	114.40	N/A	N/A	$0.57 per share	1.19
VSTM Verastem	$87.53M	7.37	N/A	N/A	$0.74 per share	9.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
EIKN Eikon Therapeutics	-$324.25M	-$4.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	-$90.60M	-$0.53	N/A	N/A	N/A	N/A	-83.75%	-66.53%	11/11/2026 (Estimated)
VSTM Verastem	-$209.47M	-$2.66	N/A	N/A	N/A	-231.59%	-467.49%	-94.54%	11/3/2026 (Estimated)

Latest TNYA, VSTM, AVTE, and EIKN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	EIKN Eikon Therapeutics	-$1.61	-$1.63	-$0.02	-$1.63	N/A	N/A
8/6/2026	Q2 2026	VSTM Verastem	-$0.4305	-$0.35	+$0.0805	-$0.35	$22.88 million	$40.08 million
8/5/2026	Q2 2026	TNYA Tenaya Therapeutics	-$0.0683	-$0.20	-$0.1317	-$0.20	$10.00 million	$1.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
EIKN Eikon Therapeutics	N/A	9.89	9.89
TNYA Tenaya Therapeutics	N/A	4.52	4.52
VSTM Verastem	1.48	2.25	2.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
EIKN Eikon Therapeutics	N/A
TNYA Tenaya Therapeutics	90.54%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
EIKN Eikon Therapeutics	N/A
TNYA Tenaya Therapeutics	2.53%
VSTM Verastem	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
EIKN Eikon Therapeutics	384	54.17 million	N/A	N/A
TNYA Tenaya Therapeutics	110	224.23 million	218.56 million	Optionable
VSTM Verastem	50	90.56 million	88.81 million	Optionable

TNYA, VSTM, AVTE, and EIKN Headlines

Recent News About These Companies

Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform

August 31 at 7:50 AM | seekingalpha.com

Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 27, 2026 | americanbankingnews.com

Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from Analysts

August 27, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Shares Down 8.6% - Should You Sell?

August 20, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Shares Up 6.4% - What's Next?

August 17, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

Verastem (VSTM) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Hennion & Walsh Asset Management Inc. Acquires 347,872 Shares of Verastem, Inc. $VSTM

August 12, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Posts Earnings Results, Beats Estimates By $0.08 EPS

August 7, 2026 | marketbeat.com

Verastem Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Verastem (NASDAQ:VSTM) Shares Gap Up Following Better-Than-Expected Earnings

August 7, 2026 | marketbeat.com

Verastem Restructures Oberland Financing to Support Commercialization

August 7, 2026 | tipranks.com

Verastem, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 7, 2026 | seekingalpha.com

Verastem Reiterated as Buy on Strong AVMAPKI FAKZYNJA Momentum, VS-7375 Progress; $18 Price Target Maintained

August 7, 2026 | tipranks.com

Verastem: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

August 6, 2026 | finance.yahoo.com

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Moderate Buy" by Brokerages

August 2, 2026 | marketbeat.com

Verastem’s TARGET-D 202 Trial Puts Fresh Focus on KRAS G12D Lung Cancer

July 30, 2026 | tipranks.com

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic ...

July 30, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, VSTM, AVTE, and EIKN Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$20.84 -0.45 (-2.11%)

As of 08/28/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Eikon Therapeutics NASDAQ:EIKN

$10.57 -0.41 (-3.73%)

As of 02:21 PM Eastern

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

Tenaya Therapeutics NASDAQ:TNYA

$0.68 -0.01 (-1.30%)

As of 02:21 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Verastem NASDAQ:VSTM

$7.12 -0.10 (-1.39%)

As of 02:21 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNYA, VSTM, AVTE, and EIKN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNYA, VSTM, AVTE, and EIKN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNYA, VSTM, AVTE, and EIKN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, VSTM, AVTE, and EIKN Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Eikon Therapeutics NASDAQ:EIKN

Tenaya Therapeutics NASDAQ:TNYA

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNYA, VSTM, AVTE, and EIKN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNYA, VSTM, AVTE, and EIKN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNYA, VSTM, AVTE, and EIKN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, VSTM, AVTE, and EIKN Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Eikon Therapeutics NASDAQ:EIKN

Tenaya Therapeutics NASDAQ:TNYA

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools